Comments

Atossa Therapeutics Analyst Ratings

ATOSNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$0.7339

0.01922.69%

Last update: Dec 16, 9:48 AM

Overview News Earnings Options

Analyst Ratings

Insider Trades Short Interest Stock Report

Consensus Rating¹

Buy

Highest Price Target¹

$8.00

Lowest Price Target¹

$4.00

Consensus Price Target¹

$6.33

Atossa Therapeutics Analyst Ratings and Price Targets | NASDAQ:ATOS | Benzinga

Atossa Therapeutics Inc has a consensus price target of $6.33 based on the ratings of 4 analysts. The high is $8 issued by Ascendiant Capital on December 8, 2025. The low is $4 issued by Craig-Hallum on June 5, 2025. The 3 most-recent analyst ratings were released by Ascendiant Capital on December 8, 2025, September 22, 2025, and June 6, 2025, respectively. With an average price target of $7.75 between Ascendiant Capital, there's an implied 955.93% upside for Atossa Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

Sep

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

Ascendiant Capital

Craig-Hallum

HC Wainwright & Co.

¹calculated from analyst ratings

Analyst Ratings for Atossa Therapeutics

					Get Alert
Dec 8, 2025	989.99%	Edward WooAscendiant Capital 54%	7.75 8	Previous Buy Current Buy	Get Alert
Sep 22, 2025	955.93%	Edward WooAscendiant Capital 54%	7.5 7.75	Previous Buy Current Buy	Get Alert
Jun 6, 2025	921.87%	Edward WooAscendiant Capital 54%	7.25 7.5	Previous Buy Current Buy	Get Alert
Jun 5, 2025	445%	Albert LoweCraig-Hallum 56%	4	Previous Initiates Current Buy	Get Alert
Apr 21, 2025	887.81%	Edward WooAscendiant Capital 54%	7 7.25	Previous Buy Current Buy	Get Alert
Mar 26, 2025	853.74%	Emily BodnarHC Wainwright & Co. 46%	7 7	Previous Buy Current Buy	Get Alert
Mar 12, 2025	853.74%	Emily BodnarHC Wainwright & Co. 46%	7 7	Previous Buy Current Buy	Get Alert
Jan 30, 2025	853.74%	Emily BodnarHC Wainwright & Co. 46%	7 7	Previous Buy Current Buy	Get Alert
Dec 13, 2024	853.74%	Emily BodnarHC Wainwright & Co. 46%	7 7	Previous Buy Current Buy	Get Alert
Dec 12, 2024	—	Emily BodnarHC Wainwright & Co. 46%	—	Previous Buy Current Buy	Get Alert
Dec 9, 2024	853.74%	Edward WooAscendiant Capital 54%	6.5 7	Previous Buy Current Buy	Get Alert
Nov 13, 2024	853.74%	Emily BodnarHC Wainwright & Co. 46%	6 7	Previous Buy Current Buy	Get Alert
Nov 5, 2024	717.49%	Emily BodnarHC Wainwright & Co. 46%	6 6	Previous Buy Current Buy	Get Alert
Oct 31, 2024	717.49%	Emily BodnarHC Wainwright & Co. 46%	6 6	Previous Buy Current Buy	Get Alert
Sep 11, 2024	785.62%	Edward WooAscendiant Capital 54%	6.25 6.5	Previous Buy Current Buy	Get Alert
Aug 12, 2024	717.49%	Emily BodnarHC Wainwright & Co. 46%	6 6	Previous Buy Current Buy	Get Alert
Jun 28, 2024	717.49%	Emily BodnarHC Wainwright & Co. 46%	6 6	Previous Buy Current Buy	Get Alert
Jun 20, 2024	—	Louise ChenCantor Fitzgerald 60%	—	Previous Current Overweight	Get Alert
Jun 6, 2024	751.56%	Edward WooAscendiant Capital 54%	6 6.25	Previous Buy Current Buy	Get Alert
May 14, 2024	—	Louise ChenCantor Fitzgerald 60%	—	Previous Current Overweight	Get Alert
May 13, 2024	717.49%	Emily BodnarHC Wainwright & Co. 46%	4 6	Previous Buy Current Buy	Get Alert
Apr 16, 2024	445%	Emily BodnarHC Wainwright & Co. 46%	4 4	Previous Buy Current Buy	Get Alert
Apr 2, 2024	445%	Emily BodnarHC Wainwright & Co. 46%	4 4	Previous Buy Current Buy	Get Alert
Feb 12, 2024	445%	Emily BodnarHC Wainwright & Co. 46%	4	Previous Initiates Current Buy	Get Alert
Sep 8, 2023	581.25%	Louise ChenCantor Fitzgerald 60%	5	Previous Initiates Current Overweight	Get Alert

FAQ

What is the target price for Atossa Therapeutics (ATOS) stock?

The latest price target for Atossa Therapeutics (NASDAQ:ATOS) was reported by Ascendiant Capital on December 8, 2025. The analyst firm set a price target for $8.00 expecting ATOS to rise to within 12 months (a possible 989.99% upside). 8 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Atossa Therapeutics (ATOS)?

The latest analyst rating for Atossa Therapeutics (NASDAQ:ATOS) was provided by Ascendiant Capital, and Atossa Therapeutics maintained their buy rating.

When was the last upgrade for Atossa Therapeutics (ATOS)?

There is no last upgrade for Atossa Therapeutics

When was the last downgrade for Atossa Therapeutics (ATOS)?

There is no last downgrade for Atossa Therapeutics.

When is the next analyst rating going to be posted or updated for Atossa Therapeutics (ATOS)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atossa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atossa Therapeutics was filed on December 8, 2025 so you should expect the next rating to be made available sometime around December 8, 2026.

Is the Analyst Rating Atossa Therapeutics (ATOS) correct?

While ratings are subjective and will change, the latest Atossa Therapeutics (ATOS) rating was a maintained with a price target of $7.75 to $8.00. The current price Atossa Therapeutics (ATOS) is trading at is $0.73, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.